You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

XTORO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Xtoro patents expire, and what generic alternatives are available?

Xtoro is a drug marketed by Fonseca Biosciences and is included in one NDA. There are four patents protecting this drug.

This drug has forty-two patent family members in eighteen countries.

The generic ingredient in XTORO is finafloxacin. Additional details are available on the finafloxacin profile page.

DrugPatentWatch® Generic Entry Outlook for Xtoro

Xtoro was eligible for patent challenges on December 17, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 2, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for XTORO
International Patents:42
US Patents:4
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 44
Patent Applications: 101
DailyMed Link:XTORO at DailyMed
Drug patent expirations by year for XTORO
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for XTORO
Generic Entry Date for XTORO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SUSPENSION/DROPS;OTIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XTORO

XTORO is protected by four US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of XTORO is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XTORO

Methods for treating ophthalmic, otic, or nasal infections
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ACUTE OTITIS EXTERNA

Methods for treating otic infections
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ACUTE OTITIS EXTERNA

Finafloxacin suspension compositions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ACUTE OTITIS EXTERNA

Compositions and methods for treating ophthalmic, octic, or nasal infections
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fonseca Biosciences XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Fonseca Biosciences XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Fonseca Biosciences XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Fonseca Biosciences XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XTORO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fonseca Biosciences XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 ⤷  Try a Trial ⤷  Try a Trial
Fonseca Biosciences XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for XTORO

When does loss-of-exclusivity occur for XTORO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 7372
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 10266120
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 1016257
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 65852
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 11003327
Estimated Expiration: ⤷  Try a Trial

China

Patent: 2470139
Estimated Expiration: ⤷  Try a Trial

Patent: 5687111
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 48587
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 84012
Estimated Expiration: ⤷  Try a Trial

Patent: 12532115
Estimated Expiration: ⤷  Try a Trial

Patent: 15134827
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 12000136
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 70731
Estimated Expiration: ⤷  Try a Trial

Patent: 12103458
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1109492
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1541823
Estimated Expiration: ⤷  Try a Trial

Patent: 120114211
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 94775
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 60181
Estimated Expiration: ⤷  Try a Trial

Patent: 1102395
Estimated Expiration: ⤷  Try a Trial

Uruguay

Patent: 758
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XTORO around the world.

Country Patent Number Title Estimated Expiration
Spain 2694775 ⤷  Try a Trial
Taiwan 201102395 Compositions and methods for treating ophthalmic, otic, or nasal infections ⤷  Try a Trial
Poland 191193 ⤷  Try a Trial
Canada 2888641 COMPOSITIONS DE SUSPENSION DE FINAFLOXACINE (FINAFLOXACIN SUSPENSION COMPOSITIONS) ⤷  Try a Trial
Turkey 9901754 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.